Stowarzyszenie Na Rzecz Osob Niepelnosprawnych Krok Po Kroku
- Address
- lock Available on a paid plan
Nervous System Diseases Research
At Stowarzyszenie Na Rzecz Osob Niepelnosprawnych Krok Po Kroku in Gdansk, the clinical research focus is centered on Nervous System Diseases, especially movement-related complications linked to cerebral palsy. The studies are aimed at evaluating new treatment options and understanding how well they may help improve daily function and symptom control.
- Managing dyskinesia due to cerebral palsy in pediatric and adult patients
- Assessing treatment approaches for pediatric lower limb spasticity caused by cerebral palsy
The trials at this site are designed to test whether emerging therapies can reduce involuntary movements and muscle stiffness, with the broader goal of improving mobility and quality of life for people living with these neurological conditions.
Cerebral Palsy-Related Movement Disorders
The rehabilitation department is also involved in research on specific motor symptoms associated with cerebral palsy, with attention to both children and adolescents as well as some adult participants. These studies focus on evaluating the effectiveness of new therapies for symptom relief and better functional outcomes.
- Improving chorea in dyskinesia due to cerebral palsy
- Reducing lower limb spasticity in young people with cerebral palsy
Overall, the research landscape here is compact but targeted, reflecting a small number of trials with a clear emphasis on testing treatments for movement disorders and spasticity in neurological rehabilitation.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Stowarzyszenie Na Rzecz Osob Niepelnosprawnych Krok Po Kroku
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy | Neurocrine Biosciences Inc. | Phase III | Not Recruiting | Mar 2024 | Mar 2026 |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins | 1 | Unknown | 2022-10-12 | 2022-10-12 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.